AXGN Axogen, Inc.

Nasdaq axogeninc.com


$ 16.97 $ 0.38 (2.29 %)    

Monday, 20-Oct-2025 15:59:53 EDT
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 16.97
$ 16.78
$ 16.59 x 120
$ 17.50 x 1,000
$ 16.65 - $ 17.17
$ 9.22 - $ 21.00
486,910
na
780.83M
$ 1.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-26-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 10-30-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-24-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 10-29-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 04-30-2018 03-31-2018 10-Q
31 02-28-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-initiates-coverage-on-axogen-with-buy-rating-announces-price-target-of-25

HC Wainwright & Co. analyst Yi Chen initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Tar...

 fda-pushes-back-axogen-avance-nerve-graft-decision-by-3-months

FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its fu...

 axogen-receives-fda-major-amendment-designation-delaying-avance-nerve-graft-decision

Axogen, Inc. (NASDAQ:AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug ...

 axogen-narrows-fy2025-sales-guidance-from-215439m-219185m-to-219000m-vs-216463m-est

Axogen (NASDAQ:AXGN) narrows FY2025 sales outlook from $215.439 million-$219.185 million to $219.000 million vs $216.463 millio...

 axogen-q2-adj-eps-012-beats-006-estimate-sales-5666m-beat-5264m-estimate

Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 93.55...

 canaccord-genuity-maintains-buy-on-axogen-lowers-price-target-to-24

Canaccord Genuity analyst Caitlin Cronin maintains Axogen (NASDAQ:AXGN) with a Buy and lowers the price target from $26 to $24.

 axogen-affirms-fy2025-sales-guidance-of-21544m-21919m-vs-21690m-est

Axogen (NASDAQ:AXGN) affirms FY2025 sales outlook from $215.44 million-$219.19 million to $215.44 million-$219.19 million vs $2...

 axogen-q1-adj-eps-002-misses-002-estimate-sales-4856m-beat-4832m-estimate

Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200...

 lake-street-initiates-coverage-on-axogen-with-buy-rating-announces-price-target-of-30

Lake Street analyst Frank Takkinen initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Target o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION